Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 17,200 Shares of DexCom, Inc. $DXCM

Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 18.5% during the fourth quarter, HoldingsChannel reports. The firm owned 110,044 shares of the medical device company’s stock after purchasing an additional 17,200 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in DexCom were worth $7,304,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Gradient Investments LLC increased its holdings in DexCom by 13.8% during the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after buying an additional 40,343 shares during the last quarter. Nordea Investment Management AB increased its holdings in DexCom by 118.6% during the fourth quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after buying an additional 137,986 shares during the last quarter. NEOS Investment Management LLC increased its holdings in DexCom by 58.7% during the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after buying an additional 65,066 shares during the last quarter. Banco Santander S.A. increased its holdings in DexCom by 28.9% during the third quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock valued at $16,843,000 after buying an additional 56,062 shares during the last quarter. Finally, Banque Pictet & Cie SA boosted its position in shares of DexCom by 58.2% in the fourth quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock worth $7,289,000 after purchasing an additional 40,411 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, EVP Jon Coleman sold 4,911 shares of DexCom stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the sale, the executive vice president owned 95,450 shares in the company, valued at $7,075,708.50. This trade represents a 4.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Friday, May 15th. The stock was sold at an average price of $59.91, for a total value of $101,847.00. Following the transaction, the executive vice president directly owned 109,504 shares in the company, valued at $6,560,384.64. The trade was a 1.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 42,694 shares of company stock worth $3,029,267. Corporate insiders own 0.28% of the company’s stock.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom announced it will highlight new clinical findings, product advancements, and strategic initiatives at ADA 2026, reinforcing its case for broader CGM adoption and earlier-stage diabetes intervention. Article: Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
• Positive Sentiment: Recent commentary remained constructive, with analysts and market coverage noting DexCom’s strong Q1 momentum, global CGM growth potential, and expanding international demand, which may help support the stock. Article: Here’s Why You Should Retain DexCom Stock in Your Portfolio
• Positive Sentiment: DexCom also said it plans to acquire wellness tracking company Nutrisense and launch an enhanced Stelo app, a move that could broaden its consumer health footprint and create new engagement opportunities. Article: Dexcom to acquire wellness tracking company Nutrisense, launch enhanced Stelo app
• Neutral Sentiment: DexCom EVP Jon Coleman sold shares in two transactions under a pre-arranged 10b5-1 plan. While the sales were disclosed as routine, insider selling can still weigh on sentiment. Article: SEC Form 4 filing
• Neutral Sentiment: Separate market commentary noted DexCom has lagged the Dow over the past year, even as analysts remain bullish on its longer-term outlook. Article: Is DexCom Stock Underperforming the Dow?

Analyst Ratings Changes

DXCM has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a research report on Tuesday, March 24th. Raymond James Financial set a $81.00 price target on shares of DexCom in a research report on Friday, May 1st. Truist Financial reiterated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Finally, Wells Fargo & Company dropped their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $82.63.

DexCom Price Performance

DXCM stock opened at $72.86 on Monday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The company has a fifty day simple moving average of $64.83 and a two-hundred day simple moving average of $67.04. The firm has a market capitalization of $28.11 billion, a P/E ratio of 31.14, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the business earned $0.32 EPS. Analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.